Q2 Earnings Forecast for ELDN Issued By Leerink Partnrs

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for Eledon Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their prior estimate of ($0.29). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.19) EPS and FY2029 earnings at ($0.50) EPS.

A number of other equities analysts have also weighed in on ELDN. Wall Street Zen raised Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday. Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a "buy" rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Trading Up 1.0%

NASDAQ ELDN traded up $0.03 on Monday, reaching $3.05. 175,430 shares of the company were exchanged, compared to its average volume of 272,701. The business's fifty day moving average price is $3.12 and its 200 day moving average price is $3.89. The stock has a market capitalization of $182.64 million, a P/E ratio of -1.52 and a beta of 0.08. Eledon Pharmaceuticals has a fifty-two week low of $2.30 and a fifty-two week high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.20.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock valued at $33,000 after buying an additional 6,412 shares during the last quarter. CW Advisors LLC acquired a new position in shares of Eledon Pharmaceuticals in the 1st quarter worth approximately $34,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Eledon Pharmaceuticals in the 1st quarter worth approximately $41,000. Alpine Global Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $56,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $66,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).